Patents by Inventor Frank J. DELFINO
Frank J. DELFINO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10683354Abstract: The present invention provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PRLR with high affinity. In certain embodiments, the invention includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments, the invention includes antibodies that bind PRLR but do not block prolactin-mediated cell signaling. The antibodies of the invention may be fully human antibodies. The invention includes anti-PRLR antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers as well as other PRLR-related disorders.Type: GrantFiled: September 18, 2018Date of Patent: June 16, 2020Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Nicholas J. Papadopoulos, Gavin Thurston, Jessica R. Kirshner, Marcus P. Kelly, Thomas Nittoli, Frank J. Delfino
-
Publication number: 20190241667Abstract: The present invention provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PRLR with high affinity. In certain embodiments, the invention includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments, the invention includes antibodies that bind PRLR but do not block prolactin-mediated cell signaling. The antibodies of the invention may be fully human antibodies. The invention includes anti-PRLR antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers as well as other PRLR-related disorders.Type: ApplicationFiled: September 18, 2018Publication date: August 8, 2019Inventors: Nicholas J. Papadopoulos, Gavin Thurston, Jessica R. Kirshner, Marcus P. Kelly, Thomas Nittoli, Frank J. Delfino
-
Patent number: 10106616Abstract: The present invention provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PRLR with high affinity. In certain embodiments, the invention includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments, the invention includes antibodies that bind PRLR but do not block prolactin-mediated cell signaling. The antibodies of the invention may be fully human antibodies. The invention includes anti-PRLR antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers as well as other PRLR-related disorders.Type: GrantFiled: May 22, 2017Date of Patent: October 23, 2018Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Nicholas J. Papadopoulos, Gavin Thurston, Jessica R. Kirshner, Marcus P. Kelly, Thomas Nittoli, Frank J. Delfino
-
Publication number: 20180094066Abstract: The present invention provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PRLR with high affinity. In certain embodiments, the invention includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments, the invention includes antibodies that bind PRLR but do not block prolactin-mediated cell signaling. The antibodies of the invention may be fully human antibodies. The invention includes anti-PRLR antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers as well as other PRLR-related disorders.Type: ApplicationFiled: May 22, 2017Publication date: April 5, 2018Inventors: Nicholas J. PAPADOPOULOS, Gavin Thurston, Jessica R. Kirshner, Marcus P. Kelly, Thomas Nittoli, Frank J. Delfino
-
Patent number: 9688764Abstract: The present invention provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PRLR with high affinity. In certain embodiments, the invention includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments, the invention includes antibodies that bind PRLR but do not block prolactin-mediated cell signaling. The antibodies of the invention may be fully human antibodies. The invention includes anti-PRLR antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers as well as other PRLR-related disorders.Type: GrantFiled: February 23, 2016Date of Patent: June 27, 2017Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Nicholas J. Papadopoulos, Gavin Thurston, Jessica R. Kirshner, Marcus P. Kelly, Thomas Nittoli, Frank J. Delfino
-
Patent number: 9545451Abstract: The present invention provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PRLR with high affinity. In certain embodiments, the invention includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments, the invention includes antibodies that bind PRLR but do not block prolactin-mediated cell signaling. According to certain embodiments, the invention includes antibodies that bind to the first fibronectin-like type III domain of the extracellular domain of PRLR. The antibodies of the invention may be fully human antibodies. The invention includes anti-PRLR antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers as well as other PRLR-related disorders.Type: GrantFiled: October 31, 2014Date of Patent: January 17, 2017Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Nicholas J. Papadopoulos, Gavin Thurston, Jessica R. Kirshner, Marcus P. Kelly, Thomas Nittoli, Frank J. Delfino, William C. Olson, Yashu Liu
-
Publication number: 20160251442Abstract: The present invention provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PRLR with high affinity. In certain embodiments, the invention includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments, the invention includes antibodies that bind PRLR but do not block prolactin-mediated cell signaling. The antibodies of the invention may be fully human antibodies. The invention includes anti-PRLR antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers as well as other PRLR-related disorders.Type: ApplicationFiled: February 23, 2016Publication date: September 1, 2016Inventors: Nicholas J. PAPADOPOULOS, Gavin THURSTON, Jessica R. KIRSHNER, Marcus P. KELLY, Thomas NITTOLI, Frank J. DELFINO
-
Patent number: 9302015Abstract: The present invention provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PRLR with high affinity. In certain embodiments, the invention includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments, the invention includes antibodies that bind PRLR but do not block prolactin-mediated cell signaling. The antibodies of the invention may be fully human antibodies. The invention includes anti-PRLR antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers as well as other PRLR-related disorders.Type: GrantFiled: August 20, 2014Date of Patent: April 5, 2016Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Nicholas J. Papadopoulos, Gavin Thurston, Jessica R. Kirshner, Marcus P. Kelly, Thomas Nittoli, Frank J. Delfino
-
Publication number: 20150056221Abstract: The present invention provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PRLR with high affinity. In certain embodiments, the invention includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments, the invention includes antibodies that bind PRLR but do not block prolactin-mediated cell signaling. The antibodies of the invention may be fully human antibodies. The invention includes anti-PRLR antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers as well as other PRLR-related disorders.Type: ApplicationFiled: August 20, 2014Publication date: February 26, 2015Inventors: Nicholas J. PAPADOPOULOS, Gavin THURSTON, Jessica R. KIRSHNER, Marcus P. KELLY, Thomas NITTOLI, Frank J. DELFINO
-
Publication number: 20150056222Abstract: The present invention provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PRLR with high affinity. In certain embodiments, the invention includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments, the invention includes antibodies that bind PRLR but do not block prolactin-mediated cell signaling. According to certain embodiments, the invention includes antibodies that bind to the first fibronectin-like type III domain of the extracellular domain of PRLR. The antibodies of the invention may be fully human antibodies. The invention includes anti-PRLR antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers as well as other PRLR-related disorders.Type: ApplicationFiled: October 31, 2014Publication date: February 26, 2015Inventors: Nicholas J. PAPADOPOULOS, Gavin THURSTON, Jessica R. KIRSHNER, Marcus P. KELLY, Thomas NITTOLI, Frank J. DELFINO, William C. OLSON, Yashu LIU